Home/Pipeline/GIM-122

GIM-122

Cancer

PreclinicalActive

Key Facts

Indication

Cancer

Phase

Preclinical

Status

Active

Company

Georgiamune

About Georgiamune

Georgiamune is a private, preclinical-stage biotech leveraging a proprietary target discovery platform to develop novel immunomodulators. The company's strategy centers on rebalancing the immune system with first-in-class assets, including a dual-functioning antibody for cancer and small molecules that either inhibit or activate regulatory T cells (Tregs) for cancer and autoimmune diseases, respectively. Headquartered in Gaithersburg, MD, Georgiamune is building a portfolio aimed at large indications with high unmet need. It operates as a pre-revenue company with a team experienced in biopharma R&D.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active